Nipocalimab not checked
Johnson & Johnson (Janssen) · JNJ-80202135 · JNJ-86507083
FollowEvery change as it happens, and a Monday email
Trials
11 active
23 in total · 13 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Nipocalimab will be administered as an intravenous infusion.”In the company’s words, NCT05912517 on ClinicalTrials.gov
- Tested for
- Myasthenia Gravis (3 trials), Thrombocytopenia, Neonatal Alloimmune (2 trials), Sjogrens Syndrome, Hemolytic Disease of the Fetus and Newborn, Lupus Erythematosus, Systemic, Warm Autoimmune Hemolytic Anemia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.”In the company’s words, NCT04951622 on ClinicalTrials.gov
- Other names
- JNJ-80202135 · JNJ-86507083 · M281 · M281/JNJ-80202135
Other drugs for Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up9
- 15 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 4 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 16 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 5 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 6 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 5 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2028-01-01 to 2027-02-04 · ClinicalTrials.gov NCT06741969
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 17 Nov 2023 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | |
| Phase 3Active, not recruiting | 4 Feb 2027 | Nipocalimab in Moderate to Severe Sjogren's Disease | |
| Phase 3Recruiting | 5 Aug 2027 | A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) | |
| Phase 3Recruiting | 28 Sep 2027 | Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | |
| Phase 3Recruiting | 15 Dec 2027 | A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) | |
| Phase 3Recruiting | 6 Dec 2028 | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | |
| Phase 3Recruiting | 5 Dec 2029 | A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) | |
| Phase 2/3Active, not recruiting | 2 Feb 2025 | Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | |
| Phase 2/3Recruiting | 15 Dec 2026 | Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |
| Phase 2/3Recruiting | 30 Jun 2027 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | |
| Phase 1Recruiting | 16 Feb 2027 | A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women | |
| Phase 2Completed | 10 Aug 2022 | A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis | |
| Phase 2Completed | 23 Oct 2023 | A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) | |
| Phase 2Completed | 30 Apr 2024 | A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus | |
| Phase 2Completed | 5 Aug 2024 | A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) | |
| Phase 2Completed | 29 Aug 2024 | A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis | |
| Phase 2Completed | 4 Sep 2025 | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies | |
| Phase 2Withdrawn | 28 Feb 2028 | A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis | |
| Phase 1Completed | 26 May 2022 | A Study of Nipocalimab in Healthy Male and Female Participants | |
| Phase 1Completed | 27 May 2022 | A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants | |
| Phase 1Completed | 9 Sep 2022 | A Study of JNJ-80202135 in Healthy Chinese Adult Participants | |
| Phase 1Completed | 4 Oct 2023 | A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants | |
| Phase 1Ended | not given | A Phase I, Open-Label, Two-Part, Multiple-Dose, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Delivered Subcutaneously via Syringe and Prefilled Syringe Autoinjector in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026